White Paper AGA: Gastroparesis: Clinical and Regulatory Insights for Clinical Trials

Pankaj Jay Pasricha, Michael Camilleri, William L. Hasler, Henry P. Parkman

Research output: Contribution to journalArticle

Abstract

Gastroparesis continues to represent a large unmet clinical need and a major opportunity for new drug development. This has led to increasing interest by federal funding agencies, regulatory bodies, and industry. This article summarizes the proceedings of the gastroparesis section of the “Drug Development Conference: Clinical Endpoints in Upper GI Disorders” organized by the American Gastroenterological Association in Washington, DC, on October 27–28, 2016. The presentation, diagnosis, and current therapeutic strategies are briefly reviewed, followed by a detailed discussion of the regulatory strategy, recommended endpoints, and future directions.

Original languageEnglish (US)
Pages (from-to)1184-1190
Number of pages7
JournalClinical Gastroenterology and Hepatology
Volume15
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Gastroparesis
Clinical Trials
Pharmaceutical Preparations
Industry
Therapeutics
Direction compound

Keywords

  • Clinical Trial Design
  • Endpoints
  • Gastroparesis

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

White Paper AGA : Gastroparesis: Clinical and Regulatory Insights for Clinical Trials. / Pasricha, Pankaj Jay; Camilleri, Michael; Hasler, William L.; Parkman, Henry P.

In: Clinical Gastroenterology and Hepatology, Vol. 15, No. 8, 01.08.2017, p. 1184-1190.

Research output: Contribution to journalArticle

Pasricha, Pankaj Jay ; Camilleri, Michael ; Hasler, William L. ; Parkman, Henry P. / White Paper AGA : Gastroparesis: Clinical and Regulatory Insights for Clinical Trials. In: Clinical Gastroenterology and Hepatology. 2017 ; Vol. 15, No. 8. pp. 1184-1190.
@article{aa4ab977e952495a824181e544ef83b4,
title = "White Paper AGA: Gastroparesis: Clinical and Regulatory Insights for Clinical Trials",
abstract = "Gastroparesis continues to represent a large unmet clinical need and a major opportunity for new drug development. This has led to increasing interest by federal funding agencies, regulatory bodies, and industry. This article summarizes the proceedings of the gastroparesis section of the “Drug Development Conference: Clinical Endpoints in Upper GI Disorders” organized by the American Gastroenterological Association in Washington, DC, on October 27–28, 2016. The presentation, diagnosis, and current therapeutic strategies are briefly reviewed, followed by a detailed discussion of the regulatory strategy, recommended endpoints, and future directions.",
keywords = "Clinical Trial Design, Endpoints, Gastroparesis",
author = "Pasricha, {Pankaj Jay} and Michael Camilleri and Hasler, {William L.} and Parkman, {Henry P.}",
year = "2017",
month = "8",
day = "1",
doi = "10.1016/j.cgh.2017.04.011",
language = "English (US)",
volume = "15",
pages = "1184--1190",
journal = "Clinical Gastroenterology and Hepatology",
issn = "1542-3565",
publisher = "W.B. Saunders Ltd",
number = "8",

}

TY - JOUR

T1 - White Paper AGA

T2 - Gastroparesis: Clinical and Regulatory Insights for Clinical Trials

AU - Pasricha, Pankaj Jay

AU - Camilleri, Michael

AU - Hasler, William L.

AU - Parkman, Henry P.

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Gastroparesis continues to represent a large unmet clinical need and a major opportunity for new drug development. This has led to increasing interest by federal funding agencies, regulatory bodies, and industry. This article summarizes the proceedings of the gastroparesis section of the “Drug Development Conference: Clinical Endpoints in Upper GI Disorders” organized by the American Gastroenterological Association in Washington, DC, on October 27–28, 2016. The presentation, diagnosis, and current therapeutic strategies are briefly reviewed, followed by a detailed discussion of the regulatory strategy, recommended endpoints, and future directions.

AB - Gastroparesis continues to represent a large unmet clinical need and a major opportunity for new drug development. This has led to increasing interest by federal funding agencies, regulatory bodies, and industry. This article summarizes the proceedings of the gastroparesis section of the “Drug Development Conference: Clinical Endpoints in Upper GI Disorders” organized by the American Gastroenterological Association in Washington, DC, on October 27–28, 2016. The presentation, diagnosis, and current therapeutic strategies are briefly reviewed, followed by a detailed discussion of the regulatory strategy, recommended endpoints, and future directions.

KW - Clinical Trial Design

KW - Endpoints

KW - Gastroparesis

UR - http://www.scopus.com/inward/record.url?scp=85030624024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85030624024&partnerID=8YFLogxK

U2 - 10.1016/j.cgh.2017.04.011

DO - 10.1016/j.cgh.2017.04.011

M3 - Article

C2 - 28410896

AN - SCOPUS:85030624024

VL - 15

SP - 1184

EP - 1190

JO - Clinical Gastroenterology and Hepatology

JF - Clinical Gastroenterology and Hepatology

SN - 1542-3565

IS - 8

ER -